NanoViricides Inc. (NNVC)

[FORZANANO]

The Next Big Biotech Trades: NNVC, APPY Under the Trading Microscope:


http://www.smallcapnetwork.com/The-Next-Big-Biotech-Trades-NNVC-APPY-Under-the-Trading-Microscope/s/via/1789/article/view/p/mid/2/id/86/

NanoViricides Inc. is the developer of 'FluCide' - a flu treatment that has shown to be even more effective than oseltamivir (aka 'Tamiflu') is a therapy for certain strains of flu. Specifically, NNVC verified in preclinical trials that FluCide was more effective than Tamiflu when used against H3N2 (the most common strain of seasonal flu), and it's also shown tremendous response against H1N1. The real game-changing aspect of this drug, however, is that it's orally administered. Before FluCide, most orally-dosed flu antiviral simply didn't work well enough.

As effective as the drug may be, it's not like NanoViricides is anywhere near getting it to the market. It's yet to be tested on humans, and would need to go through three separate phases of testing (which could take years, and millions of dollars) before ready to request a final approval from the FDA. But, as veteran biotech investors know, NNVC is where so many other now-successful biotech firms have been. As long as the company shows incremental progress, the market will continue to reward the company with more funding, and a higher stock price. That being said...

NNVC has just hinted of a new uptrend by crossing back above its 200-day moving average line today. It's the second time we've seen a bullish cross of the long-term moving average in the past five weeks, and this one looks like it's going to stick; it's been in the works for a while. Indeed, it looks like NanoViricides are now finding support from other key moving average lines, which has been resistance up until this point.